期刊文献+

RNA干扰抑制MGMT表达对人脑胶质瘤化疗的影响 被引量:2

Effect of Inhibiting MGMT Gene Expression by RNA Interference on the Chemosensitivity of Giloma Cell Line
原文传递
导出
摘要 目的应用小干扰RNA(siRNA)质粒载体抑制人脑胶质瘤T98细胞系中O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)基本的表达,了解其对胶质瘤细胞化疗敏感性的影响。方法通过LipofectimineTM2000将针对MG-MT的siRNA质粒载体转入T98细胞中。采用实时定量PCR法测定MGMT mRNA的表达,Western blot测定MGMT蛋白的表达。MTT法测定转染前后T98细胞系对卡氮芥(BCNU)的敏感性变化。结果成功构建针对MGMT基因的siRNA质粒载体;质粒载体转染T98细胞后,对其MGMT mRNA的抑制率达87%,MGMT蛋白表达量明显减少,转染后的T98细胞对BCNU的敏感性增加,提高了约6倍。结论针对MGMT基因的siRNA质粒载体可以靶向抑制MGMT基因在T98细胞系中的表达,增加T98细胞对BCNU的敏感性。 Objective To investigate the effect of combinative samll interference RNA(siRNA) vectors targeting O6-methylguanine DNA methyltransferase(MGMT) gene on chemosensitivity of the glioma cell line.Methods T98 cells with MGMT siRNA vectors were transfected by LipofectamineTM 2000.Real-time quantitative polymerase chain reaction was used to detect the expression of MGMT mRNA.Expression of MGMT protein was detected by Western blot.And MTT was used to assesse the sensitivity of T98 cell to alkylating agent.Results The combinative siRNA vectors were successfully constructed.MGMT mRNA and protein expression level was dramatically suppressed in the transfected T98 cells,which was 87%.The sensitivity of T98 cells to BCNU had increased after transfected with MGMT siRNA vectors,which was 6 times.Conclusion RNA interference mediated by the combinative siRNA vectors can significantly down-regulate the expression of MGMT in glioma cell line T98 and increases its chemosensitivity to BCNU.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2010年第4期711-714,共4页 Suzhou University Journal of Medical Science
基金 江苏省科教兴卫医学重点人才基金资助项目(RC2007081)
关键词 O6-甲基鸟嘌呤-DNA甲基转移酶 RNA干扰 小干扰RNA 转染 O6-methylguanine DNA methyltransferase RNA interference small interference RNA transfection
  • 相关文献

参考文献4

二级参考文献40

  • 1周晓平,卢旺盛,沈茜,刘建民,岳志健,许奕,洪波,姜秀峰.TIMP-2对人脑胶质瘤U87体外侵袭力的抑制作用[J].中华神经外科杂志,2005,21(1):48-50. 被引量:7
  • 2黄强,浦佩玉,夏之柏,蒋元文,尤永平,张云亭,王春燕,王广秀.wt-p53基因联合HSV-TK/GCV对C6鼠胶质瘤杀伤作用的实验研究[J].中华神经外科杂志,2005,21(5):269-273. 被引量:9
  • 3孟庆海,宫安静,李洛.树突状细胞活化的CTLs对神经胶质瘤的体外杀伤作用研究[J].中华神经外科杂志,2005,21(7):427-431. 被引量:4
  • 4祁震宇,惠国桢,张世明,李瑶,周宗祥,顾少华,应康,谢毅.一条人脑胶质瘤相关新基因的克隆与表达[J].中华神经外科杂志,2006,22(2):96-100. 被引量:2
  • 5赵世光,滕雷,赵洪波,刘耀华,甄云波,张娜,唐海涛,杨宝峰.荧光引导鼠脑胶质瘤切除的实验研究[J].中华神经外科杂志,2006,22(2):120-122. 被引量:32
  • 6Balana C, Ramirez JL, Taron M, et al. O6 methylguanine DNA methyltransferase Methylation in Serum and Tumor DNA Predicts Response to 1,3 Bis(2 Chloroethyl) 1 Nitrosourea but not to Temozolamide Plus Cisplatin in Glioblastoma Multiforme [J]. Clin Cancer Res, 2003, 9(4): 1461- 1468.
  • 7Andratachke N, Grosu AL, Molls M, et al. Perspectives in the treament of malignant gliomas in adults [J]. Anticancer Res, 2001, 21(5):3541- 3550.
  • 8Silber JR, Bobola MS, Ghatan S, et al. O6 methylguanine DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics [J]. Cancer Res, 1998, 58(5): 1068- 1073.
  • 9Silber JR, Blank A, Bobola MS, et al. O6 methylguanine DNA methltransferase deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent based chemotherapy [J]. Clin Cancer Res, 1999, 5(4): 807- 814.
  • 10Nutt CL, Loktionova NA, Pegg AE, et al. O(6) methylguanine DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes [J]. Carcinogenesis, 1999, 20(12): 2361- 2365.

共引文献73

同被引文献17

  • 1Sung MT, Jones TD, Beck SD. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy [ J ]. Hum Pathol, 2006, 37 (6) :662 - 667.
  • 2Chen Z, Xu WR, Qian H, et al. Oct 4, a novel marker for human gastric cancer[J]. Journal of surgical oncology, 2009, 99(7) :414 -419.
  • 3Monk M, Hitchins M, Hawes S. Differential expression of the embryo/cancer gene ECSA ( DPPA2 ), the cancer/testis gene BORIS and the pluripotency structural gene OCTal, in human preimplantation development [ J ]. MOL HUM REPROD, 2008, 14(6) :347 -355.
  • 4Livak K J, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCT Method[J]. Methods, 2001, 25(4) :402-408.
  • 5Gidekel S, Pizov G, Bergman Yet al. Oct3/4 is a dose-dependent oncogenic fate determinant [J]. Cancer Cell, 2003,4(5 ) :361 - 370.
  • 6Chang CC, Shieh GS, Wu P, et al. Oct3/4 Expression reflects tumor progression and regulates motility of bladder cancer cells [ J ]. Cancer Res, 2008,68 ( 15 ) : 6281 - 6291.
  • 7Stupp R,Mason WP,van den Bent MJ,et al.Radiothera-py plus concomitant and adjuvant temozolomide for glio-blastoma[J].N Engl J Med,2005,352(10):987-996.
  • 8Ohgaki H,Kleihues P.Epidemiology and etiology of glio-mas[J].Acta Neuropathol,2005,109(1):93-108.
  • 9Xie F,Shi Q,Wang Q,et al.CD40 is a regulator for vas-cular endothelial growth factor in the tumor microenvironmentof glioma[J].J Neuroimmunol,2010,222(1-2):62-69.
  • 10Pluvinet R,Petriz J,Torras J,et al.RNAi-mediated si-lencing of CD40 prevents leukocyte adhesion on CD154-ac-tivated endothelial cells[J].Blood,2004,104(12):3642-3646.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部